Clinical trials: Trastuzumab
Breast Cancer
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
This single arm study will evaluate alterations in molecular marker expression in HER2-positive targeted therapy, and will evaluate the effect of continued treatment with Herceptin and Xeloda beyond progression following initial…
- Trial name
- NCT00885755
- Testing
- Standard taxane therapy, capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 13 sites in Australia, Spain and 2 more
- Volunteers
- 33 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Gastric Cancer
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive…
- Trial name
- NCT01522768
- Testing
- Afatinib and Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-mutant Non-Small Cell Lung Cancer
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
- Trial name
- DL-05 (NCT05246514)
- Testing
- Trastuzumab deruxtecan
- Where
- 28 sites in China
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Breast Cancer
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the…
- Trial name
- NCT00193063
- Testing
- Trastuzumab, Gemcitabine
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.
- Trial name
- NCT01579578
- Testing
- AZD8931, Paclitaxel
- Where
- 15 sites in Germany, Japan and 3 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Advanced Breast Cancer, HER2-positive Breast Cancer
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
- Conditions
- Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- DEBBRAH (NCT04420598)
- Testing
- Trastuzumab deruxtecan
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 41 people
- Sponsor
- MedSIR
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
- Trial name
- NCT02536339
- Testing
- Pertuzumab, Trastuzumab
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
HER2-positive Breast Cancer, Metastatic Breast Cancer
Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer
Trastuzumab combined with chemotherapy has been approved as the first line therapy in HER2+ metastatic breast cancer. When patients experienced progression beyond trastuzumab containing therapy, T-DM1 is considered as the second…
- Trial name
- NCT03755141
- Testing
- Herzuma
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- National Cancer Center, Korea
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in treating patients with HER2 positive stage…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT04108858
- Testing
- Copanlisib, Pertuzumab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
We proposed to use 4 cycles of AC q 2 weeks, as used in the dose dense adjuvant study with GM-CSF support on days 3-9 of the cycle.
- Trial name
- NCT00256243
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Rita Sanghvi, Mehta
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT01196390
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 634 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Positive Breast Cancer
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together.
- Trial name
- HER2CLIMB-04 (NCT04539938)
- Testing
- tucatinib, trastuzumab deruxtecan
- Where
- 140 sites in United States
- Volunteers
- 70 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone…
- Conditions
- Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00238420
- Testing
- Paclitaxel, Radiation Therapy, Trastuzumab
- Where
- 184 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well trastuzumab works in treating patients with locally advanced or metastatic gallbladder cancer or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer
- Trial name
- NCT00478140
- Testing
- trastuzumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal…
- Trial name
- NCT01269346
- Testing
- Eribulin Mesylate
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eisai Inc.
Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
- Trial name
- NCT00258960
- Testing
- Liposomal Doxorubicin, Cyclophosphamide, Trastuzumab
- Where
- 12 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Spanish Breast Cancer Research Group